Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Stays In Hot Seat On Capitol Hill; PDUFA No Longer Drives Legislation

Executive Summary

FDA operational problems will continue to be a prime target for congressional oversight, a House Republican staffer advised the Food and Drug Law Institute annual meeting April 23

You may also be interested in...



FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report

FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future

FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report

FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future

IRB Quality Concerns Take Center Stage After FDA Clamps Down On Coast

Quality has moved up in importance as a criterion for selecting an institutional review board following an April 14 FDA warning letter to Coast IRB and the company's agreement to halt enrollment in clinical studies it monitors

Related Content

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel